Skip to content

About OmicsX

From Drug Intelligence to Decision Governance.

OmicsX has spent years mapping drug targets, modalities, developers, vendors, and innovation activity across oncology and advanced drug discovery. That intelligence now powers a new generation of governed decision systems - built to determine what should proceed, what should pause, and what should stop before capital compounds risk.

Not reports. Not open-ended consulting. Governed decision systems for drug discovery.

WHY OMICSX EXISTS

Drug discovery does not fail only from lack of data

Drug discovery does not fail only from lack of data.

The harder problem is knowing when evidence is strong enough to support progression - and when it is not.

Weak evidence should not carry expensive decisions.

ABOUT OMICSX

Fifteen years of mapping drug development became the foundation for decision systems.

OmicsX began by mapping cancer drug targets and oncology innovation activity. Over time, that work expanded into monitoring drug developers, clinical research organizations, emerging modalities, platform companies, vendors, and business-development activity across global drug discovery.

That accumulated intelligence revealed a recurring pattern: programs rarely fail only because information is missing. They fail because targets, molecules, modalities, vendors, and capital decisions move forward before proof is ready.

Today, OmicsX converts that accumulated intelligence into pre-built governance systems with established decision points, required outputs, evidence boundaries, permission logic, and decision records.

WHAT WE BUILD

Decision Operating Systems for Drug Discovery

Target-Scoped Decision System

A target-to-asset governance system that determines whether a difficult target; and the molecules against it -deserve progression.

Decision OS

A modality and program governance system for ADC, DAC, Molecular Glue, Extracellular TPD and other complex development pathways.

Vendor OS

An execution governance system that ensures vendor-dependent work produces decision-useful evidence, not disconnected deliverables.

Different Systems. One Operating Belief : Progression must be earned by Proof

WHAT MAKES OMICSX DIFFERENT

We do not produce more information. We govern how information becomes a decision.

Traditional Approach

OmicsX Approach

Reports summarize information

Systems govern Decisions

Consulting responds to a brief

pre-built systems define what must be proven

Progression is argued narratively

Progression is permissioned

Outputs are recommendations

Outputs are governed decision records

WHO WE SERVE

Build for Teams making expensive scientific decisions.

Biotech Founders & CSOs

Deciding whether a target, molecule or modality should advance.

Platform Companies

Managing multiple assets, targets and molecules.

BD & Strategy Teams

Evaluating external molecules, platforms and partnership opportunities.

Investors & Boards

Allocating capital across uncertain programs wit defensible evidence.

Program & Vendor Leaders

Ensuring execution remains traceable, comparable and decision-useful.